AbelZeta Pharma — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

AbelZeta Pharma is a clinical-stage biotechnology company pioneering T cell-based therapies for hematologic malignancies, solid tumors, and inflammatory/immunological diseases. The company leverages a proprietary CAR-T platform and is led by a management team with deep experience from major technology and pharmaceutical corporations. While currently a private, pre-revenue entity, it is advancing a pipeline of novel cell therapies with the aim of providing personalized treatments for challenging conditions.

Hematologic MalignanciesInflammatory & Immunological DiseasesSolid Tumors

Technology Platform

Proprietary Chimeric Antigen Receptor (CAR)-T cell platform for developing T cell-based therapeutics.

Opportunities

The company is targeting large, high-need markets in oncology and immunology, with a particular opportunity in applying CAR-T technology to solid tumors and autoimmune diseases, where current options are limited.

Success in these areas could lead to transformative therapies and significant market value.

Risk Factors

Key risks include clinical trial failure, especially in the technically challenging areas of solid tumors and new immunological indications, intense competition in the cell therapy space, and dependence on private financing to fund costly development and manufacturing activities.

Competitive Landscape

AbelZeta operates in the highly competitive cell and gene therapy sector, competing against large pharma companies with approved CAR-T products (e.g., Gilead/Kite, Bristol Myers Squibb, Novartis) and numerous clinical-stage biotechs developing next-generation autologous and allogeneic cell therapies for cancer and autoimmune diseases.

More companies in Cell & Gene Therapy →More companies in United States →